Table 3 Clinical Endpoints in the Long-term Follow-up Study as Grouped by Additional NA Treatment
|  | PEG-IFN alfa-2b 1.0mcg/kg/wk 24 weeks | PEG-IFN alfa-2b 1.5mcg/kg/wk 24 weeks | PEG-IFN alfa-2b 1.5mcg/kg/wk 48 weeks | Total | ||||
|---|---|---|---|---|---|---|---|---|
Without NAs n = 65 | Additional NAs n = 49 | Without NAs n = 56 | Additional NAs n = 41 | Without NAs n = 58 | Additional NAs n = 53 | Without NAs n = 179 | Additional NAs n = 143 | |
HBe Negativity | 46 (70.8) | 30 (61.2) | 43 (76.8) | 23 (56.1) | 46 (79.3) | 31 (58.5) | 135 (75.4) | 84 (58.7) |
ALT Normalization | 48 (73.8) | 38 (77.6) | 40 (71.4) | 39 (95.1) | 41 (70.7) | 45 (84.9) | 129 (72.1) | 122 (85.3) |
HBe(−) + ALT Normalization | 36 (55.4) | 26 (53.1) | 35 (62.5) | 22 (53.7) | 38 (65.5) | 29 (54.7) | 109 (60.9) | 77 (53.8) |
SR | 40 (61.5) | 22 (44.9) | 36 (64.3) | 19 (46.3) | 40 (69.0) | 22 (41.5) | 116 (64.8) | 63 (44.1) |
CR | 23 (35.4) | 17 (34.7) | 16 (28.6) | 18 (43.9) | 29 (50.0) | 21 (39.6) | 68 (38.0) | 56 (39.2) |
HBsAg any decrease ^ | 32 (49.2) | 30 (61.2) | 23 (41.1) | 18 (43.9) | 34 (58.6) | 31 (58.5) | 89 (49.7) | 79 (55.2) |
Decompensated Liver Event* | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.7) |